Harmony Biosciences
HRMY
296 hedge funds and large institutions have $1.31B invested in Harmony Biosciences in 2025 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 116 increasing their positions, 88 reducing their positions, and 26 closing their positions.
244% more call options, than puts
Call options by funds: $30.8M | Put options by funds: $8.95M
69% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 26
32% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 88
6% more funds holding
Funds holding: 279 → 296 (+17)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6.87% less ownership
Funds ownership: 89.25% → 82.38% (-6.9%)
19% less capital invested
Capital invested by funds: $1.62B → $1.31B (-$314M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$13.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11.8M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$9.02M |
| 4 |
BA
Bridgewater Associates
Westport,
Connecticut
|
+$7.29M |
| 5 |
Renaissance Technologies
New York
|
+$7.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
Valor Management
Chicago,
Illinois
|
-$184M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$31.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$29M |
| 4 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$11.8M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$4.02M |
HRMY Hedge Fund Activity: Q3 2025 in Review
296 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q3 2025, worth a combined $1.31B — down 19% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new HRMY positions and 26 closed out — a net gain of 18 holders — while 116 added to existing stakes and 88 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $13.4M. The largest seller was Valor Management, cutting an estimated $184M.
- 296 institutional investors held Harmony Biosciences (HRMY) as of Q3 2025, up from 279 in Q2 2025.
- Funds reported $1.31B of Harmony Biosciences stock for Q3 2025, down 19% quarter-over-quarter.
- 44 funds opened new Harmony Biosciences positions in Q3 2025 and 26 closed out, a net change of +18 holders.
- The largest Harmony Biosciences buyer in Q3 2025 was Arrowstreet Capital, an estimated $13.4M added.
- The largest Harmony Biosciences seller in Q3 2025 was Valor Management, an estimated $184M sold.
Based on aggregated 13F filings for Q3 2025.